Table 3
Outcomes of patients undergoing VA–ECLS using a univariable and multivariable regression analysis.
| Variables | OR (95% CI) | p-value | aORa (95% CI) | Adjusted p-value |
|---|---|---|---|---|
| Mortality | ||||
| Mild vs Ref. | 1.2 (0.6–2.3) | 0.43 | 1.3 (0.6–2.8) | 0.66 |
| Moderate vs Ref. | 1.2 (0.6–2.5) | 0.47 | 1.3 (0.6–3.1) | 0.70 |
| Severe vs Ref. | 2.7 (1.0–7.4) | 0.04 | 2.5 (0.9–7.4) | 0.10 |
| Any Cardiovascular or Renal complication | ||||
| Mild vs Ref. | 0.9 (0.6–2.3) | 0.12 | 0.8 (0.4–2.4) | 0.06 |
| Moderate vs Ref. | 0.8 (0.6–2.5) | 0.12 | 0.9 (0.3–2.4) | 0.23 |
| Severe vs Ref. | 4.3 (0.9–20.7) | 0.04 | 4.6 (0.9–23.0) | 0.03 |
| Stage II/III AKI** | ||||
| Mild vs Ref. | 0.9 (0.4–2.1) | 0.16 | 0.9 (0.4–2.4) | 0.19 |
| Moderate vs Ref. | 0.8 (0.3–1.9) | 0.09 | 0.9 (0.3–2.4) | 0.14 |
| Severe vs Ref. | 6.5 (0.8–53.9) | 0.06 | 6.2 (0.7–53.5) | 0.07 |
Reference group = Normoxia (PaO2 ≤ 100). Mild Hyperoxia (PaO2 = 101–200 mmHg); Moderate Hyperoxia (PaO2 = 201–300 mmHg); Severe Hyperoxia (PaO2 > 300 mmHg). **Stage II AKI: Stage 2: serum creatinine increase of 2–2.9 times baseline, or UO < 0.5 mL/kg/h for ≥ 12 h; Stage III AKI: serum creatinine increase ≥ 3 times baseline or ≥ 4 mg/dL, or UO < 0.3 mL/kg/h for ≥ 24 h or anuria ≥ 12 h, or need for renal replacement therapy. a Adjusted for age group, BSA, indication for ECLS.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.